A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Praxis Precision Medicines

Criteria

Inclusion Criteria:

1. Recurrent MDD diagnosis with a current episode duration of at least 8 weeks and no more than 24 months.

2. HAM-D17 total score of ≥23 at Screening and Baseline.

3. Body mass index (BMI) between 18 and 38 kg/m2 (inclusive).

Exclusion Criteria:

1. Lifetime history of seizures, including febrile seizures.

2. Neurodegenerative disorder (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, or Huntington's disease).

3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive compulsive disorder or a history of a psychotic mood episode in last 2 years.

4. Any current psychiatric disorder (other than MDD).

5. Lifetime history of treatment resistant depression.

6. Received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) within the last year or transcranial magnetic stimulation (TMS) within the last 6 months prior to Screening.

7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females.